LCG
BPMC

Lisanti Capital Growth’s Blueprint Medicines BPMC Stock Holding History

Lisanti Capital Growth’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-26,150
Closed -$2.09M – 102
2019
Q1 		$2.09M Buy
+26,150
New +$1.93M 0.74% 61
2018
Q2 		– Sell
-24,860
Closed -$2.28M – 140
2018
Q1 		$2.28M Buy
24,860
+5,650
+29% +$487K 1.1% 37
2017
Q4 		$1.45M Buy
19,210
+5,015
+35% +$353K 0.83% 48
2017
Q3 		$989K Buy
+14,195
New +$759K 0.62% 70

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Lisanti Capital Growth's BPMC Position: Q2 2019 in Review

Lisanti Capital Growth sold out of Blueprint Medicines (BPMC) in Q2 2019, closing a stake of 26,150 shares — an estimated $2.09M sold.

Lisanti Capital Growth first reported a position in BPMC in Q3 2017 and held it in 4 quarters. The position peaked at $2.28M in Q1 2018. 220 funds tracked by Wall St. Rank hold BPMC as of Q2 2019.

  • Lisanti Capital Growth reported no remaining Blueprint Medicines position as of Q2 2019 after selling out during the quarter.
  • Lisanti Capital Growth sold 26,150 Blueprint Medicines shares in Q2 2019, an estimated $2.09M.
  • Lisanti Capital Growth first reported a position in Blueprint Medicines in Q3 2017 and held it in 4 quarters.
  • Lisanti Capital Growth's Blueprint Medicines position peaked at $2.28M in Q1 2018.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2019.

Based on Lisanti Capital Growth's 13F filing for Q2 2019, filed 5 Aug 2019.